Nondiabetic kidney disease

New England Journal of Medicine

Volumn 347, Issue 19, 2002, Pages 1505-1511

  Levey, Andrew S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN; VERAPAMIL; ANTILIPEMIC AGENT;

AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CASE REPORT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ECHOGRAPHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING; CHRONIC KIDNEY FAILURE; CLASSIFICATION; PRACTICE GUIDELINE; SMOKING CESSATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; DIET, PROTEIN-RESTRICTED; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; PRACTICE GUIDELINES; SMOKING CESSATION;

EID: 0037038234     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp013462     Document Type: Review

References (43)

1. Excerpts from the 2000 United States Renal Data System annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2000;36:Suppl 2.
2. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
3. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39:Suppl 2:S1-S246.
4. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998;32:853-906.
5. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920-9.
6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-70.
7. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:A0828. abstract.
8. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-7.
9. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10.
10. American Diabetes Association. Clinical practice recommendations 2001: Diabetic nephropathy. Diabetes Care 2001;24:Suppl 1:S69-S72.
11. Smith HW. Comparative physiology of the kidney. In: Smith HW, ed. The Kidney: Structure and Function in Health and Disease. New York: Oxford University Press, 1951:520-74.
12. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950;29:496-507.
13. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 1992;38:1933-53.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.
16. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
17. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
18. Douglas J. African American Study of Kidney Disease and Hypertension study results. Presented at the American Heart Association Scientific Sessions, Anaheim, Calif., November 11-14, 2001. abstract.
19. Lazarus JM, Bourgoignie J, Buckalew V, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997;29:641-50.
20. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
21. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
22. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64.
23. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and the progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
24. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001;285:2719-28.
25. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
26. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.
27. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 2000;14:295-301.
28. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-80.
29. Basta E, Bakris GL. Evolution of drugs that preserve renal function. J Clin Pharmacol 2000;40:978-89.
30. National Research Council. Recommended Dietary Allowances. 10th Ed. Washington, D.C.: National Academy Press, 1989.
31. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: What have all the results of the MDRD study shown? J Am Soc Nephrol 1999;10:2426-39.
32. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 1996;124:627-32.
33. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay endstage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000;15:1986-92.
34. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000;35:Suppl 2:S1-S140.
35. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998;32:Suppl 3:S142-S156.
36. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-III). Bethesda, Md.: National Institutes of Health, 2001. (NIH publication no. 01-3670.)
37. Fried LF, Orchard TJ, Kasiske BL. The effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260-9.
38. Blane GE. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987;83:Suppl 5B:26-36.
39. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-9.
40. Beto JA, Bansal VK. Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 1998;32:Suppl 3:S172-S183.
41. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997;51:1669-77.
42. Striker G. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. J Am Soc Nephrol 1995;5:1537-40.
43. Counseling to prevent tobacco use. In: Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd Ed. Baltimore: Williams & Wilkins, 1996:597-609.